Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere length is an independent prognostic marker in MDS but not in de novo AML

Telomere dysfunction is implicated in the generation of large‐scale genomic rearrangements that drive progression to malignancy. In this study we used high‐resolution single telomere length analysis (STELA) to examine the potential role of telomere dysfunction in 80 myelodysplastic syndrome (MDS) an...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Williams, J, Heppel, N, Britt-Compton, B, Grimstead, J, Jones, R, Tauro, S, Bowen, D, Knapper, S, Groves, M, Hills, R, Pepper, C, Baird, D, Fegan, C
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Wiley 2017

Antzeko izenburuak

Telomere length is a critical determinant for survival in multiple myeloma
nork: Hyatt, S, et al.
Argitaratua: (2017)

Maintenance of telomere length in AML
nork: Peter M. Lansdorp
Argitaratua: (2017-11-01)

Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
nork: Nadia El Menshawy, et al.
Argitaratua: (2020-07-01)

Inherited predisposition to MDS/AML
nork: Ana Rio Machin, et al.
Argitaratua: (2018-06-01)

Telomerase activity and telomere length in AML-M3 patients
nork: Hamidollah Ghaffari, et al.
Argitaratua: (2009-04-01)

Telomerase activity and telomere length in AML-M3 patients
nork: Hamidollah Ghaffari, et al.
Argitaratua: (2009-06-01)

T cell memory revisited using single telomere length analysis
nork: Laureline Roger, et al.
Argitaratua: (2023-09-01)

PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML
nork: Barbara De Moerloose
Argitaratua: (2023-12-01)

Gene expression profiling in MDS and AML: potential and future avenues.
nork: Theilgaard-Mönch, K, et al.
Argitaratua: (2011)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
nork: Jensen O, et al.
Argitaratua: (2022-02-01)

Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities
nork: Olga K. Weinberg, et al.
Argitaratua: (2023-08-01)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
nork: Hoyle, C, et al.
Argitaratua: (1989)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
nork: Goh, Chermaine Yu Zhen
Argitaratua: (2021)

p53 biology and reactivation for improved therapy in MDS and AML
nork: Joanna E. Zawacka
Argitaratua: (2024-03-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
nork: V. Sheth, et al.
Argitaratua: (2022-06-01)

P739: THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML
nork: A. G. Lema Fernandez, et al.
Argitaratua: (2022-06-01)

PERFORMANCE OF CYTOGENETIC TESTS IN AML AND MDS SAMPLES PROCESSED IN A REMOTE LABORATORY IN BRAZIL
nork: A Amaro, et al.
Argitaratua: (2024-10-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
nork: Petra Bašová, et al.
Argitaratua: (2025-01-01)

Paclitaxel Induced MDS and AML: A Case Report and Literature Review
nork: Udit Bhaskar Bhatnagar, et al.
Argitaratua: (2016-01-01)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
nork: Azra Raza, et al.
Argitaratua: (2020-01-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
nork: Christoforos K. Vaxevanis, et al.
Argitaratua: (2023-12-01)

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
nork: YE Xiangjun, LU Xingguo
Argitaratua: (2023-10-01)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
nork: V. Van Oorschot, et al.
Argitaratua: (2022-06-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
nork: Hongjiao Li, et al.
Argitaratua: (2023-09-01)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
nork: Lixian Chang, et al.
Argitaratua: (2022-09-01)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
nork: Guancui Yang, et al.
Argitaratua: (2022-10-01)

Telomere length in myelodysplastic syndromes.
nork: Boultwood, J, et al.
Argitaratua: (1997)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
nork: Barreyro, L, et al.
Argitaratua: (2012)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
nork: Anson Snow, et al.
Argitaratua: (2022-07-01)

TELOMERE LENGTH AND ATHEROSCLEROSIS
nork: O. M. Drapkina, et al.
Argitaratua: (2016-09-01)

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
nork: Zuzana Tothova, et al.
Argitaratua: (2021-02-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
nork: T. Ueda, et al.
Argitaratua: (2024-01-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
nork: A. Shastri, et al.
Argitaratua: (2024-01-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
nork: Sandra Huber, et al.
Argitaratua: (2023-08-01)

Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML
nork: Laura Barreyro, et al.
Argitaratua: (2024-06-01)

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis
nork: Victoria V. Grunwald, et al.
Argitaratua: (2019-09-01)

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
nork: Amer M. Zeidan, et al.
Argitaratua: (2024-06-01)

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
nork: Tahsin Anwar, et al.
Argitaratua: (2023-12-01)

Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS
nork: Peter Vandenberghe, et al.
Argitaratua: (2011-06-01)

Telomere length in myelodysplastic syndromes.
nork: Boultwood, J, et al.
Argitaratua: (1995)